Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression

Drug Safety

Volumn 18, Issue 1, 1998, Pages 57-82

  Mourilhe, Patricia ^a   Stokes, Peter E ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450; FLUOXETINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

CLINICAL TRIAL; DEPRESSION; DRUG OVERDOSE; DRUG PROTEIN BINDING; DYSTHYMIA; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; NEUROTOXICITY; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SUICIDE;

ADULT; AGED; DEPRESSIVE DISORDER; FEMALE; HUMANS; PREGNANCY; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 0031965230     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199818010-00005     Document Type: Review

References (182)

1. Kalon W, Von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67-76
2. Wells KB, Katon W, Rogers B, Camp P. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the medical outcomes study. Am J Psychiatry 1994; 151: 694-700
3. Stokes PE. Fluoxetine: a five year review. Clin Ther 1993; 15: 216-43
4. Thase ME, Kupfer DJ. Recent developments in the pharmacotherapy of mood disorders. J Consult Clin Psychol 1996; 64: 646-59
5. Regier DA, Hirschfeld RM, Goodwin FK, et al. The NIMH Depression Awareness, Recognition, and Treatment Program: structure, aims, and scientific basis. Am J Psychiatry 1988; 145: 1351-7
6. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic-depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277 (4): 333-40
7. Shelton RC, Davidson J, Yonker KA, et al. The undertreatment of dysthymia. J Clin Psychiatry 1997; 58 (2): 59-65
8. Richelson E. Treatment of acute depression. Psych Clin North America 1993; 16 (3): 461-78
9. Wong DT, Bymaster FP, Horng JS, et al. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-methyl- 3-phenylpropylamine. J Pharmacol Exp Ther 1975; 193: 804-11
10. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 56 Suppl. 6: 12-21
11. Kroenke K. Discovering depression in medical patients: reasonable expectations. Ann Intern Med 1997; 126 (6): 463-5
12. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270: 1819-25
13. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262: 914-9
14. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994; 55 Suppl. 12: 3-15
15. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 971-83
16. Haddad LM. Managing tricyclic antidepressant overdose. Am Fam Phys 1992; 46: 153-9
17. Tollefson GD. Selective serotonin reuptake inhibitors. In: Schatzberg AF, Nemeroff B, editors. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press, Inc., 1995: 161-82
18. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897-902
19. Sclar DA, Robinson LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16 (4): 715-30
20. Sclar DA, Robinson LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evalualion of fluoxetine, paroxetine, and sertraline in a health maintenance organisation. J Int Med Res 1995; 23: 395-412
21. Stoudemire A, Frank R, Hedemark N, et al. The economic burden of depression. Gen Hosp Psychiatry 1986; 8: 387-94
22. Katon W. The epidemiology of depression in medical care. Int J Psychiatry Med 1987; 17: 93-112
23. Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry 1970; 117: 437-8
24. Mann JJ, Kapur S. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry 1991; 48: 1027-33
25. Avery D, Winokur G. Suicide, attempted suicide, and relapse rates in depression: occurrence after ECT and antidepressant therapy. Arch Gen Psychiatry 1978; 35: 749-53
26. Hagnell O, Lanke J, Rorsman B. Suicide rates in the Lundby study: Mental illness as a risk factor for suicide. Neuropsychobiology 1981; 7: 248-53
27. Tollefson GD, Fawcett J, Winokur G, et al. Evaluation of suicidality during pharmacologic treatment of mood and non-mood disorders. Ann Clin Psychiatry 1993; 5: 209-24
28. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54 (11): 405-18
29. Katon W, Sullivan MD. Depression and chronic medical illness. J Clin Psychiatry 1990; 51 Suppl. 6: 3-11
30. Shapiro S, Skinner EA, Kessler LG, et al. Utilization of health and mental health services: three Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1984; 41: 971-8
31. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51 Suppl. 6: 60-71
32. Judd LL, Rapaport MH. Economics of depression and cost-benefit comparisons of selective serotonin reuptake inhibitors and tricyclic antidepressants. Depression 1995; 2: 173-7
33. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47 (12): 1093-9
34. Donoghue JM. A comparison of prescribing patterns of selective serotonin reuptake inhibitors in the treatment of depression in primary care in the United Kingdom. J Serotonin Res 1995; 1: 47-51
35. Tollefson GD. Antidepressant treatment and side effect consideration. J Clin Psychiatry 1991; 52 Suppl.: 4-13
36. Gerber PD, Barrett J, Barrett J, et al. Recognition of depression by internists in primary care: a comparison of internist and "gold standard" psychiatric assessment. J Gen Intern Med 1989; 4: 7-13
37. Simon GE, Von Korff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med 1995; 4: 99-105
38. Lewis-Hall FC, Wilson MG, Tepner RG, Koke SC. Fluoxetine versus tricyclic antidepressants in women with major depressive disorder. J Womens Health 1997; 6: 337-343
39. Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. AJMC 1996; 2 (9): 1239-46
40. Wong DT, Bymaster FP, Engleman EA. Minireview: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 1995; 57 (5): 411-41
41. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153 (3): 311-20
42. Keller MB. Diagnosis issues and clinical course of unipolar illness. Rev Psychiatry 1988; 7: 188-212
43. Thase ME. Relapse and recurrence in unipolar major depression: short term and long term approaches. J Clin Psychiatry 1990; 51 Suppl.: 51-9
44. Goodwin FK, Jamison KR. Course and outcome. In: Goodwin FK, Jamison KR, editors. Manic depressive illness. New York: Oxford University Press, 1990: 127-56
45. Grof P, Angst J, Haines T. The clinical course of depression: practical issues. In: Angst J, editor. Classification and prediction of outcome of depression. Symposium Schlob Reinhartshausen/Rhein; 1973 Sep 23-26. New York: FK Schattauer Verlag, 1973: 141-55
46. Consensus Development Panel. Mood disorders: pharmacologic prevention of recurrences. Am J Psychiatry 1985; 142: 469-76
47. Angst J, Bastrup P, Grof P, et al. The course of monopolar depression and bipolar psychoses. Psychiatr Neurol Neurochir (Amst) 1973; 76: 489-500
48. Angst J. Natural history and epidemiology of depression. In: Cobb J, Goeting N, editors. Results of community studies in prediction and treatment of recurrent depression. Southampton: Duphar Medical Relations, 1990
49. Lee AS, Murray AM. The long term outcome of Maudsley depressives. Br J Psychiatry 1988; 153: 741-51
50. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217-22
51. Eric L. A prospective, double-blind, comparative, multicentre study of paroxetine and placebo in preventing recurrent major depressive episodes. Biol Psychiatry 1991; 29 Suppl. 11: 254S-5S
52. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988; 153 Suppl. 3: 69-76
53. Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 1992; 43 Suppl. 2: 3-10
54. Gonzalez MB, Snyderman TB, Colket JT, et al. Depression in patients with coronary artery disease. Depression 1996; 4 (4): 57-62
55. Nesse RE, Finlayson RE. Management of depression in patients with coexisting medical illness. Am Fam Phys 1996; 53: 2125-33
56. Stoudemire A. Expanding psychopharmacologic treatment options for the depressed medical patient. Psychosomatics 1995; 36: S19-26
57. Feighner JP, Cohn JB. Double-blind comparative trial of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985; 46: 20-5
58. Baldessarini RJ. Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiatry 1989; 50: 117-26
59. Haddad LM. Managing tricyclic antidepressant overdose. Am Fam Phys 1992; 46: 153-9
60. Kasper S, Fuger JD, Moller HJ. Comparative efficacy of antidepressants. Drugs 1992; 43 Suppl. 2: 11-23
61. Feighner JP, Boyer WF, Meredith CH, et al. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989; 4: 239-44
62. Guelfi JD, Dreyfus JF, Pichot P. Fluvoxamine and imipramine: results of a long-term controlled trial. Int Clin Psychopharmacol 1987; 2: 103-9
63. Wernicke JF, Bremner JD, Bosomworth J, et al. The efficacy and safety of fluoxetine in the long-term treatment of depression. International Fluoxetine Symposium: 1987 Oct 13-17; Tyrol, Austria
64. Peselow ED, Filippi AM, Goodnick P, et al. The short and long term efficacy of paroxetine HCl. B: data from a double-blind crossover study and from a year-long term trial vs imipramine and placebo. Psychopharmacol Bull 1989; 25 (2): 272-6
65. VanPraag HM, Kahn R, Asnis GM, et al. Therapeutic indications for serotonin-potentiating compounds: a hypothesis. Biol Psychiatry 1987; 22: 205-12
66. Boyer WF, Feighner JP. The efficacy of selective serotonin uptake inhibitors in depression. In: Feighner JP, Boyer WF, editors. Selective serotonin uptake inhibitors. Chichester, England: Wiley, 1991: 89-108
67. Lader M. Fluoxetine efficacy vs comparative drugs: an overview. Br J Psychiatry 1988; 153 Suppl. 3: 51-8
68. Tollefson GD. Adverse drug reactions/interactions in maintenance therapy. J Clin Psychiatry 1993; 54 Suppl.: 48-58
69. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985; 46: 42-4
70. Fabre LF, Scharf MB, Itil TM. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. J Clin Psychiatry 1991; 52 Suppl: 62-7
71. Beasley CM, Sayler ME, Cunningham GE, et al. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990; 20: 193-200
72. Delgado PL, Price LH, Charney DS, et al. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988; 15: 55-60
73. Leonard BE. SSRI differentiation: pharmacology and pharmacokinetics. Hum Psychopharmacol 1995; 10: S149-58
74. Baumann P. Clinical pharmacokinetics of citalopram and other serotonergic reuptake inhibitors (SSRI). Int Clin Psychopharmacol 1992; 6 Suppl. 5: 13-20
75. Koe BK, Weissman A, Welch WM, et al. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 1983; 226: 686-700
76. Richelson E. Antidepressants and brain neurochemistry. Mayo Clin Proc 1990; 65: 1227-36
77. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacol Berl 1987; 93: 193-200
78. Bolden-Watson C, Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023-9
79. Tollefson GD, Rampey AH, Beasley CM, et al. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 1994; 14: 163-9
80. Wong DT, Reid LR, Bymaster FP, et al. Chronic effects of fluoxetine, a selective inhibitor of serotonin uptake, on neurotransmitter receptors. J Neural Transm 1985; 64: 251-69
81. Pérez V, Gilaberte I, Faries D, et al. Randomized, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594-7
82. Greden JF. Antidepressant maintenance medications: when to discontinue and how to stop. J Clin Psychiatry 1993; 54 Suppl.: 39-45
83. Fava G, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmacol 1995; 15 (5): 374-5
84. Prozac (fluoxetine hydrochloride) Product Information. Indianapolis (IN): Dista Products Company, 1995 May 17
85. Physicians Desk Reference. 50th ed. Montvale, NJ: Medical Economics Company, Inc. 1996; 2544-8
86. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990; 264: 2524-8
87. ® (brand of paroxetine HCL tablet) product information. SmithKline Beecham Pharmaceuticals. Philadelphia; May 1997
88. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31 (6): 444-69
89. Kulig K. Management of poisoning associated with 'newer' antidepressant agents. Ann Emerg Med 1986; 15: 1039-45
90. Montgomery SA. The benefits and risks of 5-HT uptake inhibitors in depression. Br J Psychiatry 1988; 153 (3 Suppl.): 7-10
91. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985; 45: 53-8
92. Goldstein DJ, Rampey AH Jr, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Am J Clin Nutr 1992; 55: 181S-4S
93. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabetic Med 1995; 12: 416-8
94. Kaye WH, Weltzin TE, Hsu LKG, et al. An open trial of fluoxetine in patients with anorexia nervosa. J Clin Psychiatry 1991; 52: 464-71
95. Filteau MJ, Baruch P, Lapierre YD, et al. SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients. Int Clin Psychopharmacol 1995; 10: 51-4
96. Beasley Jr CM, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303: 685-92
97. DeVane CL. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Hum Psychopharmacol 1995; 10: S185-93
98. Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin and digoxin. Acta Psychiatr Scand 1989; 80: 102-6
99. Lemberger L, Rowe H, Bosomworth JC, et al. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988; 43: 412-9
100. Shen WW, Hsu JH. Female sexual side effects associated with selective serotonin reuptake inhibitors: A descriptive clinical study of 33 patients. Int J Psychiatry Med 1995; 25: 239-48
101. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 1995; 25: 191-205
102. Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol 1997; 11: 72-82
103. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995; 152: 1514-6
104. Harvey KV, Balon R. Clinical implications of antidepressant drug effects on sexual function. Ann Clin Psychiatry 1995; 7 (4): 189-201
105. Aizenberg D, Zeimshlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropsychopharmacol 1995; 18 (4): 320-4
106. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry 1986; 21: 1067-71
107. Schatzberg AF. Dosing strategies for antidepressant agents. J Clin Psychiatry 1991; 52 (Suppl): 14-20
108. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions. I. Antidepressants and antipsychotics. J Clin Pharmacol 1983; 15: 349S-55S
109. Freshefsky L, Riesenman C, Lam YWF. Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6. Clin Pharmacokinet 1995; 29 (4 Suppl. 1): 10-9
110. Rudorfer MV, Potter WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the 'newer' vs the 'older' drugs. Drugs 1989; 37: 713-38
111. Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 1997; 17 (1): 170-2
112. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-5
113. Gregor KJ, Overhage JM, Coons SJ, et al. Selective serotonin reuplake inhibitor dose titration in the naturalistic setting. Clin Ther 1994; 16 (2): 306-15
114. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull 1944; 30 (2): 251-9
115. Cooper GL. The safety of fluoxetine: an update. Br J Psychiatry 1988; 153 (3 Suppl.): 77-86
116. Kapur S, Mieczkowski MA, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992; 268: 3441-5
117. Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry 1991; 52: 108-11
118. Jenner PN. Paroxetine: an overview of dosage, tolerability, and safety. Int Clin Psychopharmacology 1992; 4: 69-80
119. Tollefson GD, Tollefson SL, Sayler ME, et al. Absence of emergent suicidal ideation during treatment: a comparative, controlled, double-blind analysis employing several distinct antidepressants. Depression 1994; 2: 73-9
120. Grundemar L, Wohlfart B, Lagerstedt C, et al. Symptoms and signs of severe citalopram overdose [letter]. Lancet 1997; 349 (7065): 1602
121. Stanley M, Virgilio J, Gershon S. Tritiated imipramine binding sites are decreased in frontal cortex of suicides. Science 1982; 216: 1337-9
122. Åsberg M, Träskman L, Thorén P. 5-HIAA in cerebrospinal fluid - a biochemical suicide predictor? Arch Gen Psychiatry. 1976; 33: 1193-7
123. Åsberg M, Schalling D, Träskman-Bendz L, et al. Psychobiology of suicide, impulsivity, and related phenomena. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 655-68
124. Fava M, Rosenbaum JF, Pava JA, et al. Anger attacks in unipolar depression. Part I: clinical correlates and response to fluoxetine treatment. Am J Psychiatry 1993; 150: 1158-63
125. Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 1995; 5 (1): 5-13
126. Dalack GW, Roose SP. Perspective on the relationship between cardiovascular disease and affective disorder. J Clin Psychiatry 1990; 51 Suppl.: 4-9
127. Gullette ECD, Blumenthal JA, Babyak M, et al. Effects of mental stress on myocardial ischemia during daily life. JAMA 1997; 277 (20): 1521-6
128. Glassman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993; 54 Suppl. 2: 16-22
129. Bergstrom RF, Lemberger L, Farid N, et al. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988; 153 Suppl. 3: 47-50
130. Robinson RG, Price TR. Post-stroke depressive disorders: a follow-up study of 103 patients. Stroke 1982; 13: 635-41
131. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? Clin Psychiatry 1992; 53 (8); 278-82
132. Mayeux R, Stern Y, Cote L, et al. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34: 642-6
133. Goldstein DJ, Rampey Jr AH, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes 1994; 18: 129-35
134. NIH Consensus Development Panel on Depression in Late Life. Diagnosis and treatment of depression in late life. JAMA 1992; 268: 1018-24
135. Covinsky KE, Fortinsky RH, Palmer RM, et al. Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons. Ann Intern Med 1995; 126 (6): 417-25
136. Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985; 46 (3): 20-5
137. Dunner DL, Cohn JB, Walshe T III, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992; 53 Suppl. 2: 57-60
138. Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison on sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51 Suppl. B: 28-33
139. Flint AJ, Rifat SL. The effect of treatment on the two-year course of late-life depression. Br J Psychiatry 1997; 170: 268-72
140. Feighner JP, Boyer WF, Meredith CH, et al. An overview of fluoxetine in geriatric depression. Br J Psychiatry 1988; 153 Suppl. 3: 105-8
141. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269 (17): 2246-8
142. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258-62
143. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness druing pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592-606
144. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335 (14): 1010-5
145. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995; 15 (6): 417-20
146. Goldstein D, Corbin L, Sundell K. Effects of first trimester fluoxetine exposure on the newborn. Am J Obs Gyn 1997; 89 (5): 713-8
147. Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology 1996; 53: 304-8
148. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93: 137-50
149. Montgomery SA. Efficacy in long-term treatment of depression. J Clin Psychiatry 1996; 57 (2 Suppl.): 24-30
150. Stokes PE. A primary care perspective on management of acute and long-term depression. J Clin Psychiatry 1996; 54 (Suppl.): 74-84
151. Rothschild AJ, Samson JA, Bessette MP, et al. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993; 54: 338-42
152. Vestergaard P, Gram LF, Kragh-Sorensen P, et al. Therapeutic potentials of recently introduced antidepressants. Psychopharmacol Ser 1993; 10: 190-8
153. Hale AS, Stokes PE. The utility of serotonin reuptake inhibitors in endogenous and severe depression. In: Freeman HL, editor. The uses of fluoxetine in clinical practice. London: Royal Society of Medicine Services and International Congress and Symposium Series No. 183, 1991: 15-25
154. Montgomery SA. Fluoxetine in the treatment of anxiety, agitation and suicidal thoughts [abstract]. In: Stefanis CN, Soldatos CR, Rabavilas AD, editors. Psychiatry Today: VIII World Congress of Psychiatry Abstracts. New York: Elsevier, 1989: 335
155. Shaw DM, Crimmins R. A multicentre trial of citalopram and amitriptyline in major depressive illness. In: Montgomery SA, editor. Citalopram: the new antidepressant from Lundbeck Research. Amsterdam: Excerpta Medica 1989: 43-9
156. Beasley CM, Sayler ME, Bosomworth JC, et al. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol 1991; 11: 166-74
157. Tollefson GD, Holman SL, Slayer ME, Potvin JH. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry 1994; 55: 50-9
158. Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 1991; 159: 394-8
159. Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 1990; 81: 185-9
160. Chabannes JP. Antidepressant and anxiety. Psychopharmacology 1988; 96 Suppl.: 272
161. Katz MM, Koslow SH, Maas JW, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987; 17: 297-309
162. Montgomery SA, Pedersen V, Tanghoj P, et al. The optimal dosing regimen for citalopram: a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 1994; 9 Suppl. 1: 35-40
163. Fuglum E, Rosenberg C, Damsbo N, et al. Screening and treating depressed patients: a comparison of two controlled citalopram trials across treatment settings: hospitalized patients vs patients treated by their family doctors. Acta Psychiatr Scand 1996; 94 (1): 18-25
164. Haffmans PM, Timmerman L, Hoogduin CA. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. Int Clin Psychopharmacol 1996; 11 (3): 157-64
165. Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry 1996; 57 (Suppl.): 51-8
166. den Boer JA, Westenberg HGM. Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: a concise review. Hum Psychopharmacol 1995; 10: S173-83
167. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54: 435-8
168. Charney DS, Nelson JC. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry 1981; 138: 328-33
169. Hellerstein DJ, Yanowitch P, Rosenthal J, et al. Long-term treatment of double depression: a preliminary study with serotonergic antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 139-47
170. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992; 49: 809-16
171. Quitken FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988; 145 (3): 306-11
172. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45: 129-37
173. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: a subgroup of depressives with better response to MAOIs than to tricyclic antidepressants or placebo. Br J Psychiatry 1984; 41: 669-77
174. Charney DS, Miller HL, Licinio J, et al. Treatment of depression. In: Schatzberg AF, Nemeroff CB, editors. The American psychiatric press textbook of psychopharmacology. Washington, DC: American Psychiatric Press, Inc., 1995: 575-601
175. Reimherr FW, Wood DR, Byerly B, et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984; 20: 70-2
176. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47 (12): 1093-9
177. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217-22
178. Kupfer DJ, Frank E, Perel JM, et al. Five-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49 (10): 769-73
179. Fava M, Rappe SM, Pava JA, et al. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995; 56: 52-5
180. van Moffaert M, Bartholome F, Cosyns P, et al. A controlled comparison of sertraline and fluoxetine in acute and discontinuation treatment of major depression. Human Psychopharmacol 1995; 10: 393-405
181. Montgomery SA. The advantages of paroxetine in different subgroups of depression. Int Clin Psychopharmacol 1992; 6 Suppl. 4: 91-100
182. Price JS, Waller PC, Wood SM, et al. A comparison of the postmarketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42: 757-63